Printer Friendly

PROTON LABS/REGENBODY COMPLETE KOREAN TRAINING.

Proton Laboratories, Inc. CEO, Armando Casciati, has announced that Dr. Lee has returned from training with RNL Bio Ltd. in Korea and stated, "The feedback we received from the training in South Korea was extremely positive and continues to reinforce our belief in the process of utilizing adult stem cells to reinvigorate the body and allow it to heal itself. Both Dr. Lee and his assistant had the opportunity to observe, document and study in detail the work being done by RNL directly and also saw U.S. cancer patients who had flown to Korea to be treated." RNL indicated it has had a number of potential patients contact them from the U.S.; however, the difficulty of such a long flight prevented them from going.

About Proton Laboratories, Inc. and its wholly owned subsidiary RegenoBody S.A:

RegenoBody S.A., a wholly owned subsidiary of Proton Laboratories, Inc., brings the benefits of bioscience to patients who have been diagnosed with chronic debilitating diseases, offering viable, efficient therapeutic options with special Stem Cell Therapies utilizing the most effective cell regeneration techniques. Therapies are tailored for each individual, based upon their specific needs. Cells are obtained by the most modern technological methods. The transplant physicians and stem cell laboratory scientists associated with RNL Bio have been regarded as some of the best in the world. Stem cells derived from Autologous (Stem cells taken from your own body) and Allogeneic (Stem cells from a source other than your own) are used depending on the particular condition that needs to be treated. Treatments will be delivered by an experienced team of International and U.S. Board Certified Physicians who are guided by strict protocols ensuring excellence in medical care.

About RNL Bio Company LTD:

RNL Bio is a premier biopharmaceutical company focused on development and commercialization of adult stem cell therapeutics and dog cloning technology. Headquartered in Seoul with a state-of-the-art GMP facility, RNL is a publicly traded company on the Korea Exchange (Code 003190) and strives to become a global leader across the biomedical industry.
COPYRIGHT 2010 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Worldwide Biotech
Geographic Code:9SOUT
Date:Nov 1, 2010
Words:343
Previous Article:NEPTUNE KRILL OIL HEALTH CLAIMS APPROVED BY HEALTH CANADA.
Next Article:THROMBOGENICS SIGNS DEAL WITH MSD FOR MICROPLASIN SUPPLY.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters